From: A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study
Essential amino acid
(g)
%
Histidine
1.6
8%
Isoleucine
Leucine
7.0
35%
Lysine
2.4
12%
Methionine
0.6
3%
Phenylalanine
2.8
14%
Threonine
2.0
10%
Valine
Total
20.0 g
100%